Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PHVS | US
-0.12
-0.66%
Healthcare
Biotechnology
30/06/2024
04/10/2024
18.20
17.36
18.38
17.36
Pharvaris N.V. a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121 a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416 an on-demand rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719 a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands Switzerland and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden the Netherlands.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
36.2%1 month
58.5%3 months
68.9%6 months
72.0%-
-
2.70
0.00
0.00
-1.38
-
-
-116.10M
982.94M
982.94M
-
-
-
-
-45.05
5.59
1.55
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.28
Range1M
4.29
Range3M
6.04
Rel. volume
0.52
Price X volume
1.30M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Relay Therapeutics Inc. | RLAY | Biotechnology | 6.53 | 1.06B | 0.62% | n/a | 7.50% |
Autolus Therapeutics Plc | AUTL | Biotechnology | 3.98 | 1.06B | 0.25% | n/a | 54.69% |
AnaptysBio Inc | ANAB | Biotechnology | 33.98 | 1.03B | -2.91% | n/a | 3835.68% |
Aurinia Pharmaceuticals Inc | AUPH | Biotechnology | 7.12 | 1.02B | 0.00% | n/a | 23.58% |
Array BioPharma Inc | ARRY | Biotechnology | 6.45 | 979.92M | 0.62% | 67.30 | 117.68% |
Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 4.23 | 941.03M | -2.98% | n/a | 29.02% |
Silence Therapeutics plc | SLN | Biotechnology | 18.64 | 933.49M | 1.30% | n/a | 0.16% |
Prothena Corporation plc | PRTA | Biotechnology | 16.86 | 906.74M | 1.08% | n/a | 2.08% |
Zymeworks Inc | ZYME | Biotechnology | 12.57 | 893.07M | 1.45% | n/a | 4.94% |
Applied Therapeutics Inc | APLT | Biotechnology | 7.7 | 884.31M | -8.22% | n/a | 0.30% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.38 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 2.70 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 68.92 | 74.67 | Par |
Debt to Equity | 0.00 | -1.82 | Expensive |
Debt to Assets | 0.00 | 0.26 | Cheaper |
Market Cap | 982.94M | 3.73B | Emerging |